According to the interpretation of the 1961 Convention on Narcotic Drugs, it is clear that the extractions of the flowers of the cannabis plant, regardless of their percentage in THC, or whether they are male or female, are subject to supervision, even in the case of that the extraction is intended to obtain Sera Labs CBD Oil (non-controlled substance) and not THC (controlled substance). The underlying question is that extraction can be used to obtain both types of substances.
In Spain, the cultivation of cannabis, regardless of its percentage in THC, intended for the production of flowers for the extraction of any cannabinoid is subject to prior authorization from the Spanish Agency for Medicines and Health Products (AEMPS).
The AEMPS is aware of the advances that have been made regarding the therapeutic usefulness of cannabis. It must be remembered that the European Medicines Agency has approved several applications to develop medicines with Sera Labs CBD Oil for the treatment of rare diseases, such as Dravet syndrome, perinatal asphyxia or glioma. This approval means that a pharmaceutical company can benefit from the European Union’s incentives for the development of medicine, such as reduced costs and protection of competition once the medicine is put on the market.